Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Drukarch

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Life Sciences|January 1, 1990
D-2 dopamine autoreceptor selective drugs: do they really exist?B Drukarch, J C Stoof
Biochemical Pharmacology|March 8, 2000
Drug treatment of Parkinson's disease. Time for phase IIB Drukarch, F L van Muiswinkel
Expert Opinion on Investigational Drugs|January 5, 2002
Neuroprotection for Parkinson's disease: a new approach for a new millenniumB Drukarch, F L van Muiswinkel
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 8, 1999
Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cellsR Dringen, B Hamprecht, B Drukarch
Clinical Neurology and Neurosurgery|January 1, 1992
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?J C Stoof, J Booij, B Drukarch
Neuroscience|January 1, 1990
Muscarinic receptor activation attenuates D2 dopamine receptor mediated inhibition of acetylcholine release in rat striatum: indications for a common signal transduction pathwayB Drukarch, E Schepens, J C Stoof
European Journal of Pharmacology|April 17, 1991
Sustained activation does not desensitize the dopamine D2 receptor-mediated control of evoked in vitro release of radiolabeled acetylcholine from rat striatumB Drukarch, E Schepens, J C Stoof
Life Sciences|January 1, 1988
Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's diseaseB Drukarch, J E Leysen, J C Stoof
European Journal of Pharmacology|July 16, 1997
Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissueA Pinna, M Morelli, B Drukarch, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 31, 2020
Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?B Drukarch, G E Jacobs, M M M Wilhelmus
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Life Sciences|January 1, 1990
D-2 dopamine autoreceptor selective drugs: do they really exist?B Drukarch, J C Stoof
Biochemical Pharmacology|March 8, 2000
Drug treatment of Parkinson's disease. Time for phase IIB Drukarch, F L van Muiswinkel
Expert Opinion on Investigational Drugs|January 5, 2002
Neuroprotection for Parkinson's disease: a new approach for a new millenniumB Drukarch, F L van Muiswinkel
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 8, 1999
Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cellsR Dringen, B Hamprecht, B Drukarch
Clinical Neurology and Neurosurgery|January 1, 1992
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?J C Stoof, J Booij, B Drukarch
Neuroscience|January 1, 1990
Muscarinic receptor activation attenuates D2 dopamine receptor mediated inhibition of acetylcholine release in rat striatum: indications for a common signal transduction pathwayB Drukarch, E Schepens, J C Stoof
European Journal of Pharmacology|April 17, 1991
Sustained activation does not desensitize the dopamine D2 receptor-mediated control of evoked in vitro release of radiolabeled acetylcholine from rat striatumB Drukarch, E Schepens, J C Stoof
Life Sciences|January 1, 1988
Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's diseaseB Drukarch, J E Leysen, J C Stoof
European Journal of Pharmacology|July 16, 1997
Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissueA Pinna, M Morelli, B Drukarch, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 31, 2020
Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?B Drukarch, G E Jacobs, M M M Wilhelmus
Pageof 6